SOT 2015 – Challenges, Conundrums, and the “Catch 22” in Abuse Liability Testing for NDA Approvals: The Bugaboo of Biologics?

//SOT 2015 – Challenges, Conundrums, and the “Catch 22” in Abuse Liability Testing for NDA Approvals: The Bugaboo of Biologics?

SOT 2015 – Challenges, Conundrums, and the “Catch 22” in Abuse Liability Testing for NDA Approvals: The Bugaboo of Biologics?

By | 2015-05-06T10:46:55+00:00 May 6th, 2015|Video|Comments Off on SOT 2015 – Challenges, Conundrums, and the “Catch 22” in Abuse Liability Testing for NDA Approvals: The Bugaboo of Biologics?

About the Author:

MPI Research, with global headquarters in Mattawan, Mich., provides safety evaluation, discovery, bioanalytical and analytical services to the biopharmaceutical, medical device, animal health, and chemical industries. The company offers comprehensive imaging solutions including preclinical imaging, radiochemistry, and data analysis. Scientific knowledge and experience, responsiveness, integrity, trust, teamwork, and dedication to strong and enduring Sponsor relationships are the defining attributes that characterize MPI Research as a high-performance, high-quality organization that is committed to bringing safer and more effective products to the world.